{{Rsnum
|rsid=4646487
|Gene=CYP4B1
|Chromosome=1
|position=46813503
|Orientation=plus
|GMAF=0.1543
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP4B1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 72.6 | 24.8 | 2.7
| HCB | 73.7 | 24.8 | 1.5
| JPT | 66.4 | 30.1 | 3.5
| YRI | 57.1 | 36.7 | 6.1
| ASW | 64.9 | 33.3 | 1.8
| CHB | 73.7 | 24.8 | 1.5
| CHD | 59.6 | 32.1 | 8.3
| GIH | 52.5 | 41.6 | 5.9
| LWK | 70.0 | 26.4 | 3.6
| MEX | 79.3 | 15.5 | 5.2
| MKK | 73.1 | 26.3 | 0.6
| TSI | 66.7 | 31.4 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4646487
|Name_s=CYP4B1:rs4646487 C>T; NM_000779.3:c.517C>T; NP_000770.2:p.Arg173Trp
|Gene_s=CYP4B1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: T Phenotype: The CYP4B1:rs4646487 T variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s):p = 0.008 Type of association: CO; TOX
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111541
}}

{{GET Evidence
|gene=CYP4B1
|aa_change=Arg173Trp
|aa_change_short=R173W
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4646487
|overall_frequency_n=1598
|overall_frequency_d=10758
|overall_frequency=0.148541
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=20
|n_articles=1
|n_articles_annotated=1
|qualityscore_in_silico=3
|qualitycomment_in_silico=Y
|in_pharmgkb=Y
|nblosum100=7
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}